Germline Testing Rates Low for Rare Urothelial Cancer

A new national study finds only 4.5% of patients with upper tract urothelial carcinoma receive recommended germline genetic testing.

Updated on Oct. 31, 2026 in Cancer

Germline Testing Rates Low for Rare Urothelial Cancer

Live Poll

Do you feel confident in your access to necessary genetic testing for potential cancer risks?

Researchers analyzing 4,783 patient cases found that germline testing for upper tract urothelial carcinoma is significantly underutilized, with only 216 patients completing the process. The findings highlight a gap in genetic screening for a cancer type where early identification of Lynch syndrome is critical.

Why it matters

Identifying Lynch syndrome early is vital for patient care, yet the low testing rate indicates many individuals may be missing out on essential genetic insights. Increasing awareness and access to these tests could improve outcomes for those with hereditary cancer predispositions.

A nationwide analysis of 4,783 patients diagnosed with upper tract urothelial carcinoma found that only 4.5% underwent germline testing. Even among patients under age 50, who are higher-risk, the testing rate was only 5.6%.

The details

The analysis identified that having a prior Lynch-spectrum cancer and male sex were associated with higher odds of receiving genetic testing, while residence in the Northeast was associated with lower odds compared to the South. Following their cancer diagnosis, eight patients were formally diagnosed with Lynch syndrome.

The study period covered the analysis of 4,783 patient cases.

Health Landscape

This study aligns with National Comprehensive Cancer Network guidelines on hereditary cancer testing but reveals a stark gap in actual implementation. The findings suggest that the medical community currently falls far short of established benchmarks for managing patients with hereditary cancer predispositions.

Patients diagnosed with upper tract urothelial carcinoma should proactively discuss hereditary cancer risk with their oncology team. If you meet the clinical criteria, ensuring you are referred for germline testing can provide critical information for both your care and that of your relatives.

The takeaway

Genetic testing remains a critical, yet underutilized tool for patients diagnosed with rare urothelial cancers. Patients are encouraged to ask their physicians if germline testing is appropriate for their specific case history.